Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://www.nature.com/articles/s43018-023-00631-x.pdf
Reference5 articles.
1. Lin, J. J. et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 31, 1725–1733 (2020). This article is a comprehensive analysis of variable on-target and off-target mechanisms of resistance to RET inhibitors.
2. Odintsov, I. et al. CIC-mediated modulation of MAPK signaling opposes receptor tyrosine kinase inhibitor response in kinase-addicted sarcoma. Cancer Res. 82, 1110 (2022). This article showed the expression of RET fusion in sarcoma and the efficacy of selpercatinib in preclinical sarcoma models.
3. Shen, T. et al. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precis. Oncol. 5, 48 (2021). This article demonstrates that ‘rooftop’ RET L730V and L730I substitutions confer resistance to RET inhibitors.
4. Colclough, N. et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin. Cancer Res. 27, 189–201 (2021). This article presents preclinical evidence of the superior brain penetrability of osimertinib and demonstrates the link between low in vitro transporter efflux ratios and increased brain penetrance in vivo.
5. Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711–1723 (2020). This article reports the clinical efficacy of osimertinib, including intracranial activity.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The never-abating excitement for targeted therapies;Nature Cancer;2023-10-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3